Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

Biologics in Plaque Psoriasis

Streamlined Drug Class Review        
Draft recommendations posted for stakeholder feedback: September 21, 2023            
End of feedback period: October 5, 2023,   

Recommendations and Reasons (draft) 

Responses to Questions from the Drug Programs (draft) 

Updated Recommendations for Biologics in Plaque Psoriasis (draft) 

Submit Feedback

 

rivaroxaban (N/A)

Therapeutic Area: Venous thromboembolic events (VTE)         
Draft recommendations posted for stakeholder feedback: September 21, 2023             
End of feedback period: October 6, 2023,         
 

Draft Recommendation and Reasons

Draft Responses to Questions from the Drug Programs

Submit Feedback

 

Open Calls for Patient and Clinician Input

Emergency Department Overcrowding in Canada: An Update                                         
End of feedback period: September, 2023

Statements of Interest

NovoTTF-200A ( Optune )                           
End of feedback period: January, 2024

Statements of Interest

2024 Watch List: Care for Children and Youth With Medical Complexity                          
End of feedback period: January, 2024

Statements of Interest

Therapeutic Area
Therapeutic Area: Advanced prostate cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Relapsed or refractory diffuse large B-cell lymphoma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Stage IIB or IIC melanoma, adjuvant
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: atopic dermatitis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Cytomegalovirus infection, prophylaxis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: atopic dermatitis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Endometrial cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Diabetes mellitus, type 2
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Ankylosing spondylitis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Schizophrenia, adults
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: